A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Beyfortus is recommended for every healthy newborn, and for some practices, that’s a lot of babies to cover. “You’re easily getting into the hundreds of thousands of dollars for a medium- ...

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

The list price for Sanofi’s antibody product, Beyfortus, is $495 a dose; babies would receive one dose. The list price for the maternal vaccine is $295 a dose, which is hefty for a vaccine.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.